Display options
Cite
Pesarrodona M, Jauset T, Díaz-Riascos ZV, et al. Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies. Adv Sci (Weinh). 2019;6(18):1900849doi: 10.1002/advs.201900849.
Pesarrodona, M., Jauset, T., Díaz-Riascos, Z. V., Sánchez-Chardi, A., Beaulieu, M. E., Seras-Franzoso, J., Sánchez-García, L., Baltà-Foix, R., Mancilla, S., Fernández, Y., Rinas, U., Schwartz, S., Soucek, L., Villaverde, A., Abasolo, I., & Vázquez, E. (2019). Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 6(18), 1900849. https://doi.org/10.1002/advs.201900849
Pesarrodona, Mireia, et al. "Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies." Advanced science (Weinheim, Baden-Wurttemberg, Germany) vol. 6,18 (2019): 1900849. doi: https://doi.org/10.1002/advs.201900849
Pesarrodona M, Jauset T, Díaz-Riascos ZV, Sánchez-Chardi A, Beaulieu ME, Seras-Franzoso J, Sánchez-García L, Baltà-Foix R, Mancilla S, Fernández Y, Rinas U, Schwartz S, Soucek L, Villaverde A, Abasolo I, Vázquez E. Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies. Adv Sci (Weinh). 2019 Jul 24;6(18):1900849. doi: 10.1002/advs.201900849. eCollection 2019 Sep 18. PMID: 31559131; PMCID: PMC6755514.
Copy Download .nbib Format: NLM
Share it on

Adv Sci (Weinh). 2019 Jul 24;6(18):1900849. doi: 10.1002/advs.201900849. eCollection 2019 Sep 18.

Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Mireia Pesarrodona, Toni Jauset, Zamira V Díaz-Riascos, Alejandro Sánchez-Chardi, Marie-Eve Beaulieu, Joaquin Seras-Franzoso, Laura Sánchez-García, Ricardo Baltà-Foix, Sandra Mancilla, Yolanda Fernández, Ursula Rinas, Simó Schwartz, Laura Soucek, Antonio Villaverde, Ibane Abasolo, Esther Vázquez

Affiliations

  1. Institut de Biotecnologia i de Biomedicina Universitat Autònoma de Barcelona Bellaterra 08193 Barcelona Spain.
  2. CIBER de Bioingeniería Biomateriales y Nanomedicina (CIBER-BBN) C/ Monforte de Lemos 3-5 28029 Madrid Spain.
  3. Vall d'Hebron Institute of Oncology (VHIO) Edifici Cellex Hospital Vall d'Hebron 08035 Barcelona Spain.
  4. Peptomyc S.L. Edifici Cellex Hospital Vall d'Hebron 08035 Barcelona Spain.
  5. Functional Validation & Preclinical Research CIBBIM-Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona 08035 Barcelona Spain.
  6. Drug Delivery & Targeting CIBBIM-Nanomedicine Vall d'Hebron Institut de Recerca (VHIR) Universitat Autònoma de Barcelona 08035 Barcelona Spain.
  7. Departament de Biologia Evolutiva Ecologia i Ciències Ambientals Facultat de Biologia Universitat de Barcelona Av. Diagonal 643 08028 Barcelona Spain.
  8. Departament de Genètica i de Microbiologia Universitat Autònoma de Barcelona Bellaterra 08193 Barcelona Spain.
  9. Leibniz University of Hannover Technical Chemistry and Life Science Callinstr. 5 30167 Hannover Germany.
  10. Helmholtz Centre for Infection Research Inhoffenstraße 7 38124 Braunschweig Germany.
  11. Institució Catalana de Recerca i Estudis Avançats (ICREA) 08010 Barcelona Spain.
  12. Department of Biochemistry and Molecular Biology Universitat Autònoma de Barcelona Bellaterra 08193 Barcelona Spain.

PMID: 31559131 PMCID: PMC6755514 DOI: 10.1002/advs.201900849

Abstract

Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44-targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types of protein materials selectively penetrate and kill CD44

Keywords: biofabrication; cancer therapy; functional amyloids; inclusion bodies; protein drug release

Conflict of interest statement

T.J. is an employee of Peptomyc S.L.; L.S. and M.E.B. are co‐founders and shareholders of the same company.

References

  1. Cancer Lett. 2000 Dec 8;161(1):17-26 - PubMed
  2. J Biol Chem. 2002 Sep 27;277(39):36329-37 - PubMed
  3. Curr Opin Mol Ther. 2003 Apr;5(2):139-47 - PubMed
  4. J Biol Chem. 2004 Feb 27;279(9):8333-42 - PubMed
  5. J Cell Sci. 2005 Nov 1;118(Pt 21):5119-28 - PubMed
  6. Int J Cancer. 2006 May 15;118(10):2381-9 - PubMed
  7. Breast Cancer Res. 2006;8(5):R59 - PubMed
  8. Nat Biotechnol. 2007 Jul;25(7):718-20 - PubMed
  9. Cancer Lett. 2008 Jul 8;265(2):206-14 - PubMed
  10. PLoS Biol. 2008 Aug 5;6(8):e195 - PubMed
  11. Nature. 2008 Oct 2;455(7213):679-83 - PubMed
  12. Science. 2009 Jul 17;325(5938):328-32 - PubMed
  13. Sci Signal. 2009 Jul 21;2(80):pe43 - PubMed
  14. Prion. 2009 Jul-Sep;3(3):139-45 - PubMed
  15. Eur J Cancer. 2010 May;46(7):1271-7 - PubMed
  16. J Biol Chem. 2010 May 28;285(22):16854-63 - PubMed
  17. Nanotechnology. 2010 May 21;21(20):205101 - PubMed
  18. Oncologist. 2011;16 Suppl 1:1-11 - PubMed
  19. Genes Dev. 2011 May 1;25(9):907-16 - PubMed
  20. Genes Cancer. 2010 Jun;1(6):532-41 - PubMed
  21. Trends Biotechnol. 2012 Feb;30(2):65-70 - PubMed
  22. Int J Mol Sci. 2011;12(11):8275-87 - PubMed
  23. Insect Biochem Mol Biol. 2012 Mar;42(3):203-11 - PubMed
  24. Adv Mater. 2012 Apr 3;24(13):1742-7 - PubMed
  25. Microb Cell Fact. 2012 May 24;11:67 - PubMed
  26. PLoS Pathog. 2012;8(6):e1002744 - PubMed
  27. Microb Cell Fact. 2012 Jun 11;11:76 - PubMed
  28. Acta Biomater. 2013 Apr;9(4):6134-42 - PubMed
  29. PLoS One. 2013;8(1):e53109 - PubMed
  30. Microb Cell Fact. 2013 Feb 07;12:16 - PubMed
  31. Genes Dev. 2013 Mar 1;27(5):504-13 - PubMed
  32. Clin Pharmacol Ther. 2013 Sep;94(3):329-35 - PubMed
  33. Acta Biomater. 2014 Mar;10(3):1354-9 - PubMed
  34. Br J Cancer. 2014 Feb 18;110(4):916-27 - PubMed
  35. Mol Cell Biol. 2014 Jul;34(14):2624-34 - PubMed
  36. Int J Pharm. 2014 Oct 1;473(1-2):286-95 - PubMed
  37. Front Microbiol. 2014 Aug 01;5:401 - PubMed
  38. Methods Mol Biol. 2015;1258:411-22 - PubMed
  39. J Biol Chem. 2015 Mar 6;290(10):6457-69 - PubMed
  40. P T. 2015 Mar;40(3):191-205 - PubMed
  41. Nanomedicine (Lond). 2015;10(5):873-91 - PubMed
  42. Colloids Surf B Biointerfaces. 2015 Jun 1;130:237-45 - PubMed
  43. Nanomedicine. 2015 Nov;11(8):1883-92 - PubMed
  44. Mol Microbiol. 2016 Jan;99(1):123-34 - PubMed
  45. Int Microbiol. 2014 Jun;17(2):65-73 - PubMed
  46. ACS Appl Mater Interfaces. 2015 Dec 30;7(51):28177-87 - PubMed
  47. Oncogene. 2016 Jun 16;35(24):3201-8 - PubMed
  48. Adv Healthc Mater. 2015 Nov 18;4(16):2557-86 - PubMed
  49. Gastroenterology. 2016 Feb;150(2):513-25.e10 - PubMed
  50. Cancer Cell. 2016 Mar 14;29(3):407-422 - PubMed
  51. Soft Matter. 2016 Apr 14;12(14):3451-60 - PubMed
  52. Oncotarget. 2016 May 24;7(21):31361-71 - PubMed
  53. Sci Rep. 2016 May 05;6:25425 - PubMed
  54. PLoS One. 2016 Oct 7;11(10):e0164073 - PubMed
  55. Sci Rep. 2016 Oct 24;6:35765 - PubMed
  56. Dev Cell. 2016 Oct 24;39(2):131-132 - PubMed
  57. Nanotechnology. 2017 Jan 6;28(1):015102 - PubMed
  58. Protein Pept Lett. 2017;24(2):94-101 - PubMed
  59. Microbiology. 2017 Apr;163(4):488-501 - PubMed
  60. Trends Biochem Sci. 2017 Sep;42(9):726-737 - PubMed
  61. Front Cell Dev Biol. 2017 Feb 23;5:10 - PubMed
  62. Annu Rev Biophys. 2017 May 22;46:23-42 - PubMed
  63. J Struct Biol. 2018 Jan;201(1):76-83 - PubMed
  64. Microb Cell Fact. 2018 Apr 7;17(1):57 - PubMed
  65. J Mol Biol. 2018 Oct 12;430(20):3657-3684 - PubMed
  66. Oncogene. 2019 Jan;38(1):140-150 - PubMed
  67. J Pathol. 2019 Feb;247(2):186-198 - PubMed
  68. FEMS Microbiol Rev. 2019 Jan 1;43(1):53-72 - PubMed
  69. Microb Cell Fact. 2019 Feb 7;18(1):33 - PubMed
  70. Sci Transl Med. 2019 Mar 20;11(484):null - PubMed
  71. Biomacromolecules. 2019 May 13;20(5):1829-1848 - PubMed
  72. Oncogene. 1995 Nov 2;11(9):1899-905 - PubMed
  73. J Cell Physiol. 1994 Aug;160(2):275-86 - PubMed
  74. Oncogene. 1996 Sep 19;13(6):1279-85 - PubMed
  75. Oncogene. 1998 Nov 12;17(19):2463-72 - PubMed

Publication Types

Grant support